  Colorectal cancer is the third most common tumor in men and the second in
women, accounting for 10% of all tumors worldwide. It ranks second in
cancer-related deaths with 9.4%, following lung cancer. The decrease in
mortality rate documented over the last 20 years has shown signs of slowing
down since 2017, necessitating concentrated actions on specific measures that
have exhibited considerable potential. As such, the technical foundation and
research evidence for blood-derived protein markers have been set, pending
comparative validation, clinical implementation and integration into an
artificial intelligence enabled decision support framework that also considers
knowledge on risk factors. The current paper aspires to constitute the driving
force for creating change in colorectal cancer screening by reviewing existing
medical practices through accessible and non-invasive risk estimation,
employing a straightforward artificial intelligence outlook.
